What is Diagnamed Holdings Corp.?
engages in the development and commercialization of AI healthcare solutions.
DGNMF · Verdict
Moderate reward · elevated risk
DGNMF stands out on volatility and balance sheet, but watch the cash flow signal.
Based on 88% data coverage
DGNMF · Verdict
Above average
Current ratio 0.32
Weak vs peers
-292% return on equity
Earnings +7.4% CAGR
Model-based scoring. For information only — not financial advice.
engages in the development and commercialization of AI healthcare solutions. The company focuses on developing BRAIN AGE BRAIN HEALTH, a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 6.07M.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.
For informational purposes only. Not financial advice.